CA3096668A1 - Compositions and methods for cancer or neoplasia assessment - Google Patents

Compositions and methods for cancer or neoplasia assessment Download PDF

Info

Publication number
CA3096668A1
CA3096668A1 CA3096668A CA3096668A CA3096668A1 CA 3096668 A1 CA3096668 A1 CA 3096668A1 CA 3096668 A CA3096668 A CA 3096668A CA 3096668 A CA3096668 A CA 3096668A CA 3096668 A1 CA3096668 A1 CA 3096668A1
Authority
CA
Canada
Prior art keywords
target
methylation
sequencing
cancer
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3096668A
Other languages
English (en)
French (fr)
Inventor
Athurva J. GORE
Jeffrey A. Gole
Rui Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Singlera Genomics Inc
Original Assignee
Singlera Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singlera Genomics Inc filed Critical Singlera Genomics Inc
Publication of CA3096668A1 publication Critical patent/CA3096668A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113—PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3096668A 2018-04-12 2019-04-08 Compositions and methods for cancer or neoplasia assessment Pending CA3096668A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862656820P 2018-04-12 2018-04-12
US62/656,820 2018-04-12
PCT/US2019/026395 WO2019199696A1 (en) 2018-04-12 2019-04-08 Compositions and methods for cancer or neoplasia assessment

Publications (1)

Publication Number Publication Date
CA3096668A1 true CA3096668A1 (en) 2019-10-17

Family

ID=68163272

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3096668A Pending CA3096668A1 (en) 2018-04-12 2019-04-08 Compositions and methods for cancer or neoplasia assessment

Country Status (10)

Country Link
US (1) US20210388445A1 (https=)
EP (1) EP3775290A4 (https=)
JP (1) JP2021520809A (https=)
KR (1) KR20210003795A (https=)
CN (1) CN112352057A (https=)
AU (1) AU2019253569A1 (https=)
CA (1) CA3096668A1 (https=)
SG (1) SG11202009866XA (https=)
TW (1) TW202012638A (https=)
WO (1) WO2019199696A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019234843B2 (en) 2018-03-13 2025-12-04 Grail, Inc. Anomalous fragment detection and classification
DE202019005627U1 (de) 2018-04-02 2021-05-31 Grail, Inc. Methylierungsmarker und gezielte Methylierungssondenpanels
WO2020069350A1 (en) 2018-09-27 2020-04-02 Grail, Inc. Methylation markers and targeted methylation probe panel
US12234514B2 (en) 2018-12-21 2025-02-25 Grail, Inc. Source of origin deconvolution based on methylation fragments in cell-free DNA samples
CA3127329A1 (en) 2019-01-24 2020-07-30 Mayo Foundation For Medical Education And Research Detecting endometrial cancer
US11795495B1 (en) * 2019-10-02 2023-10-24 FOXO Labs Inc. Machine learned epigenetic status estimator
US11702704B2 (en) 2019-10-31 2023-07-18 Mayo Foundation For Medical Education And Research Detecting ovarian cancer
CN111833965B (zh) * 2019-11-08 2024-06-04 中国科学院北京基因组研究所(国家生物信息中心) 一种尿沉渣基因组dna的分类方法、装置和用途
US20230002832A1 (en) * 2019-11-27 2023-01-05 Keio University Upper urinary tract urothelial carcinoma identification method
JP7801235B2 (ja) * 2020-03-20 2026-01-16 シングレラ・ヘルス・テクノロジーズ（シャンハイ）・リミテッド 結腸直腸新生物をスクリーニングするための方法およびキット
EP4419714A4 (en) * 2021-11-23 2025-02-26 Pleno, Inc. CODED DOSAGES
TW202328459A (zh) * 2021-12-20 2023-07-16 大陸商江蘇鵾遠生物技術有限公司 一種腫瘤檢測方法及應用
CN114959038B (zh) * 2022-06-13 2024-12-17 湖南宏雅基因技术有限公司 一种hoxa9基因甲基化检测试剂及其应用
CN117766028B (zh) * 2022-09-16 2025-03-11 深圳吉因加医学检验实验室 一种基于甲基化差异预测样本来源的方法及装置
WO2024117791A1 (ko) 2022-11-29 2024-06-06 주식회사 지씨지놈 식도암 및 위암 진단용 dna 메틸화 마커 및 이의 용도
WO2024137858A2 (en) * 2022-12-22 2024-06-27 Singlera Genomics Inc. Methods and compositions for assessing colorectal cancer
WO2024178248A1 (en) * 2023-02-22 2024-08-29 University Of Southern California Pan-cancer early detection and mrd cfdna methylation
WO2025203031A2 (en) * 2024-03-26 2025-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of cancer detection by discordant methylation in cfdna

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154663A0 (en) * 2000-09-01 2003-09-17 Epigenomics Ag Method for determining the degree of methylation of defined cytosines in genomic dna in the sequence context 5'-cpg-3'
EP2129796B1 (en) * 2007-02-21 2013-10-23 Oslo Universitetssykehus HF New markers for cancer
US20100297067A1 (en) * 2007-05-14 2010-11-25 The Johns Hopkins University Methylation markers for prostate cancer and methods of use
US7843254B2 (en) * 2007-10-31 2010-11-30 Texas Instruments Incorporated Methods and apparatus to produce fully isolated NPN-based bandgap reference
WO2009108917A2 (en) * 2008-02-29 2009-09-03 Oncomethylome Sciences, S.A. Markers for improved detection of breast cancer
WO2011112845A2 (en) * 2010-03-11 2011-09-15 Board Of Regents, The University Of Texas System Methods and compositions related to a multi-methylation assay to predict patient outcome
DK2850212T3 (da) * 2012-05-18 2020-03-23 Clinical Genomics Pty Ltd Fremgangsmåde til screening for colorektal cancer
EP2959016A4 (en) * 2013-02-21 2016-10-12 Toma Biosciences Inc METHOD, COMPOSITIONS AND NUCLEIC ACID ANALYSIS KITS
EP2886659A1 (en) * 2013-12-20 2015-06-24 AIT Austrian Institute of Technology GmbH Gene methylation based colorectal cancer diagnosis
EP3224377B1 (en) * 2014-11-25 2020-01-01 AIT Austrian Institute of Technology GmbH Diagnosis of lung cancer
US9984201B2 (en) * 2015-01-18 2018-05-29 Youhealth Biotech, Limited Method and system for determining cancer status
EP3640341B1 (en) * 2015-02-24 2022-07-27 Zymo Research Corporation Assays to determine dna methylation and dna methylation markers of cancer
WO2017048932A1 (en) * 2015-09-17 2017-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cancer detection methods
CN109563546B (zh) * 2016-05-05 2022-09-09 精密科学发展有限责任公司 通过分析甲基化dna来检测肺肿瘤

Also Published As

Publication number Publication date
US20210388445A1 (en) 2021-12-16
AU2019253569A1 (en) 2020-10-29
TW202012638A (zh) 2020-04-01
CN112352057A (zh) 2021-02-09
SG11202009866XA (en) 2020-11-27
EP3775290A4 (en) 2021-12-29
WO2019199696A1 (en) 2019-10-17
JP2021520809A (ja) 2021-08-26
KR20210003795A (ko) 2021-01-12
EP3775290A1 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
US20210388445A1 (en) Compositions and methods for cancer and neoplasia assessment
US11965157B2 (en) Compositions and methods for library construction and sequence analysis
US10072283B2 (en) Direct capture, amplification and sequencing of target DNA using immobilized primers
US20200048697A1 (en) Compositions and methods for detection of genomic variance and DNA methylation status
EP4172357B1 (en) Methods and compositions for analyzing nucleic acid
US10465241B2 (en) High resolution STR analysis using next generation sequencing
WO2021097252A1 (en) Methylation assays and uses thereof
JP2024529674A (ja) 同時での変異検出およびメチル化分析のための方法
WO2024137858A2 (en) Methods and compositions for assessing colorectal cancer
HK40041271A (en) Compositions and methods for cancer or neoplasia assessment
US20260071273A1 (en) Methods for nucleic acid sequencing
WO2025178881A1 (en) Methods and compositions for assessing tissue and organ damage

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220916

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240704

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240903

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241223

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250131

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250131

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250310

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250310

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250310

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260123

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260305

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260305